May 12, 2021 9:00 am EDT Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
May 06, 2021 8:30 am EDT Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Apr 29, 2021 8:00 am EDT Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
Mar 11, 2021 4:01 pm EST Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Mar 09, 2021 9:15 am EST Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
Mar 04, 2021 9:00 am EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
Feb 01, 2021 9:15 am EST Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
Jan 19, 2021 9:15 am EST Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
Jan 12, 2021 9:05 am EST Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Dec 29, 2020 9:15 am EST Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients